Moderna stock trades at EUR 172.26 ahead of melanoma data
Published on 09/29/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (ISIN US60770K1079) was trading at EUR 172.26 at Lang & Schwarz on September 29, 2026 at 12:15 p.m. CEST, with a minus 0.77 percent change versus the prior close of EUR 173.59. The company is approaching a closely watched oncology milestone as Phase 3 melanoma data move toward the ESMO Congress.
Melanoma data set the tone
On September 21, 2026, Moderna announced that three abstracts on intismeran autogene had been accepted for the ESMO Congress. The central presentation covers a Phase 3 study of intismeran with pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma.
The Presidential Symposium presentation is scheduled for October 24, 2026, while Moderna will host an investor webcast the same day at 7:00 p.m. CEST. The program gives investors a defined date for the next major clinical readout and keeps the oncology pipeline at the center of the stock story.
Quarterly losses remain substantial
Moderna's latest reported quarter ended June 30, 2026. In its Q2 update, Moderna reported revenue of USD 0.1 billion, down from USD 0.4 billion in Q1 2026, a sharp sequential contraction. The company also reported a Q2 GAAP net loss of USD 0.8 billion and GAAP EPS of minus USD 1.97.
The figures show why clinical execution matters for the valuation. Revenue remains below the first-quarter level, while the loss keeps the business dependent on product launches and pipeline progress rather than on current earnings power.
Analysts show a wide valuation split
UBS reiterated a Neutral rating and a USD 150.00 price target on September 22, 2026, ahead of the melanoma results, according to Investing.com. UBS said the market was looking for a hazard ratio of 0.65 or better, equivalent to a 35 percent risk reduction.
Bernstein SocGen Group maintained a Market Perform rating and a USD 45.00 price target on September 25, 2026, as reported by Investing.com. The gap between the two targets underlines how heavily Moderna's valuation depends on the melanoma program and the wider mRNA platform.
Moderna stock stays in trading
Moderna stock stood at EUR 172.26 at Lang & Schwarz on September 29, 2026 at 12:15 p.m. CEST. The quote showed a minus 0.77 percent change versus the Lang & Schwarz prior close of EUR 173.59 on September 28, 2026, while the company remained listed on Nasdaq under ticker MRNA.
Moderna stock facts
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of September 29, 2026, 12:15 p.m. CEST): EUR 172.26
- Change versus prior close: minus 0.77 percent
- Prior close Lang & Schwarz (September 28, 2026): EUR 173.59
- Market capitalization: USD 78.3 billion (as of September 28, 2026)
- 52-week range: USD 22.28-202.67 (as of September 28, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq 100
